![Deborah A. O’Neil](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Deborah A. O’Neil
Directeur Général chez NovaBiotics Ltd.
Profil
Deborah A.
O’Neil is the founder of NovaBiotics Ltd., a company founded in 2004.
She holds the title of Chief Executive & Scientific Officer at NovaBiotics Ltd.
Currently, Dr. O’Neil is a Trustee at Leap Confronting Conflict, a position she started in 2017.
Dr. O’Neil has an educational background, having studied at University College London where she obtained an undergraduate degree and a doctorate.
Postes actifs de Deborah A. O’Neil
Sociétés | Poste | Début |
---|---|---|
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Directeur Général | 01/08/2004 |
Leap Confronting Conflict
![]() Leap Confronting Conflict Investment Trusts/Mutual FundsMiscellaneous Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 06/07/2017 |
Formation de Deborah A. O’Neil
University College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Health Technology |
Leap Confronting Conflict
![]() Leap Confronting Conflict Investment Trusts/Mutual FundsMiscellaneous Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom. | Miscellaneous |